Skip to main content
AD 23 10 L banner rev

Course Details

Released On

September 3, 2025

Expires On

July 25, 2026

Media Type

Internet

Specialties

Education, Geriatric Medicine, Neurology, Primary Care, Psychiatry

Completion Time

60 minutes

Topics

Dementia, Depression, Alzheimers, Geriatric Medicine, Mental Health

Providers/Grant Support

This activity is supported by an educational grant from Lilly.

Credits Available

  • Physicians — 1.0 AMA PRA Category 1 CreditTM
  • Nurses — 1.0 ANCC contact hour

All other healthcare professionals completing this course will be issued a statement of participation

Target Audience

This activity is designed to meet the educational needs of health care providers involved in the diagnosis and continued care of patients with Alzheimer’s disease, including primary care physicians, neurologists, geriatricians, psychiatrists, and other multidisciplinary team members.

Program Overview

This program has been developed to educate health care practitioners who care for patients with Alzheimer’s disease on the importance of early diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease, timely specialist referral, and effective treatment and monitoring of patients receiving anti-amyloid therapies. It highlights the importance of a multidisciplinary, shared decision-making approach to optimize care management. This Day in the Life docuseries provides unique insights into the patient’s journey from diagnosis to treatment and the physician’s perspective on the clinical strategies for managing disease symptoms.

Learning Objectives

Upon completion of this activity, participants should be better able to: 

  • Integrate evidence-based pathways for screening, diagnosing, and staging MCI and AD
  • Appraise clinical practice recommendations informing use of DMTs for AD and identifying those who qualify for treatment based on available clinical data
  • Assess and manage potential adverse events associated with DMTs for AD using a multidisciplinary approach
  • Apply best practices for shared decision making when discussing DMT treatment for AD, including discussions of treatment benefits, risks, and what to expect with therapy

Faculty

Porsteinsson anton p

Anton P. Porsteinsson MD

William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine
Director, Alzheimer’s Disease Care, Research and Education Program (AD CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York

Patients

Steve Bancroft
Rochester, New York

Thomas Mahoney, MD
Pittsford, New York

Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.

Disclosures of Conflicts of Interest

Instructions for Participation and Credit

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/